
Jakub GoÅ,Äb.

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3750740/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. Oncogene, 2022, 41, 1600-1609.	2.6	9
2	Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. European Journal of Pharmacology, 2022, 919, 174792.	1.7	10
3	The Influence of Time of Day of Vaccination with BNT162b2 on the Adverse Drug Reactions and Efficacy of Humoral Response against SARS-CoV-2 in an Observational Study of Young Adults. Vaccines, 2022, 10, 443.	2.1	11
4	Evaluation of the Antitumor Immune Response Following Photofrin-Based PDT in Combination with the Epigenetic Agent 5-Aza-2′-Deoxycytidine. Methods in Molecular Biology, 2022, 2451, 559-567.	0.4	1
5	Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. Oncolmmunology, 2021, 10, 1956143.	2.1	30
6	Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development. Cancers, 2021, 13, 870.	1.7	28
7	Can Developments in Tissue Optical Clearing Aid Super-Resolution Microscopy Imaging?. International Journal of Molecular Sciences, 2021, 22, 6730.	1.8	2
8	The role of CD71+ erythroid cells in the regulation of the immune response. , 2021, 228, 107927.		37
9	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Research, 2021, 81, 6029-6043.	0.4	20
10	Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells. Communications Biology, 2021, 4, 1384.	2.0	12
11	Discovery of OATD-01 , a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry, 2020, 63, 15527-15540.	2.9	18
12	A New Inhibitor of Tubulin Polymerization Kills Multiple Cancer Cell Types and Reveals p21-Mediated Mechanism Determining Cell Death after Mitotic Catastrophe. Cancers, 2020, 12, 2161.	1.7	10
13	Myeloid Cell-Derived Arginase in Cancer Immune Response. Frontiers in Immunology, 2020, 11, 938.	2.2	249
14	Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 433-438.	1.3	27
15	Immunoglobulin expression and the humoral immune response is regulated by the non-canonical poly(A) polymerase TENT5C. Nature Communications, 2020, 11, 2032.	5.8	34
16	Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy. Cancer Immunology, Immunotherapy, 2020, 69, 1101-1112.	2.0	13
17	Systematic Evaluation of Chemically Distinct Tissue Optical Clearing Techniques in Murine Lymph Nodes. Journal of Immunology, 2020, 204, 1395-1407.	0.4	10
18	Tissue clearingâ€based method for unobstructed threeâ€dimensional imaging of mouse penis with subcellular resolution. Journal of Biophotonics, 2020, 13, e202000072.	1.1	1

#	Article	IF	CITATIONS
19	Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. ACS Medicinal Chemistry Letters, 2020, 11, 1228-1235.	1.3	9
20	Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis. JCI Insight, 2020, 5, .	2.3	16
21	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. Blood, 2020, 136, 33-34.	0.6	0
22	Pharmacological Induction of NOXA Sensitizes High-Risk B Cell Acute Lymphoblastic Leukemia Cells to Venetoclax. Blood, 2020, 136, 17-18.	0.6	0
23	Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases. Journal of Medicinal Chemistry, 2019, 62, 7126-7145.	2.9	22
24	Advances in Ex Situ Tissue Optical Clearing. Laser and Photonics Reviews, 2019, 13, 1800292.	4.4	52
25	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nature Communications, 2019, 10, 3000.	5.8	194
26	Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response. Oncolmmunology, 2019, 8, e1655370.	2.1	9
27	The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies. PLoS ONE, 2019, 14, e0210796.	1.1	9
28	Targeting the thioredoxin system as a novel strategy against Bâ€cell acute lymphoblastic leukemia. Molecular Oncology, 2019, 13, 1180-1195.	2.1	24
29	Cholesterol restricts lymphotoxin \hat{l}^2 receptor-triggered NF- $\hat{l}^\circ B$ signaling. Cell Communication and Signaling, 2019, 17, 171.	2.7	16
30	Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene, 2019, 38, 2860-2875.	2.6	19
31	Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biology, 2019, 21, 101062.	3.9	29
32	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncolmmunology, 2018, 7, e1423183.	2.1	23
33	Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 310-314.	1.0	13
34	Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. Journal of Medicinal Chemistry, 2018, 61, 695-710.	2.9	23
35	Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy. BMC Cancer, 2018, 18, 210.	1.1	36
36	Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. British Journal of Cancer, 2018, 119, 873-884.	2.9	49

#	Article	IF	CITATIONS
37	Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. Cancer Immunology Research, 2018, 6, 930-940.	1.6	21
38	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica, 2018, 103, 1843-1852.	1.7	8
39	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 2017, 130, 1628-1638.	0.6	40
40	Selection of an optimal promoter for gene transfer in normal B cells. Molecular Medicine Reports, 2017, 16, 3041-3048.	1.1	6
41	Photochemical delivery of bleomycin induces T-cell activation of importance for curative effect and systemic anti-tumor immunity. Journal of Controlled Release, 2017, 268, 120-127.	4.8	17
42	Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice. European Journal of Cancer, 2017, 83, 19-27.	1.3	39
43	Investigation of cell death mechanisms in human lymphatic endothelial cells undergoing photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 2016, 14, 57-65.	1.3	12
44	The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. Oncolmmunology, 2016, 5, e1182278.	2.1	31
45	Dissection of CD20 regulation in lymphoma using RNAi. Leukemia, 2016, 30, 2409-2412.	3.3	13
46	Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. Oncology Reports, 2016, 35, 3151-3158.	1.2	4
47	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. PLoS ONE, 2016, 11, e0155893.	1.1	26
48	Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. Oncotarget, 2016, 7, 1717-1731.	0.8	48
49	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology, 2015, 146, 173-183.	2.0	16
50	Review Cancer stem cells in haematological malignancies. Wspolczesna Onkologia, 2015, 1A, 1-6.	0.7	15
51	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	2.2	317
52	Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity. Frontiers in Oncology, 2015, 5, 176.	1.3	25
53	Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. Blood Cancer Journal, 2015, 5, e300-e300.	2.8	4
54	SK053 triggers tumor cells apoptosis by oxidative stress-mediated endoplasmic reticulum stress. Biochemical Pharmacology, 2015, 93, 418-427.	2.0	26

#	Article	IF	CITATIONS
55	Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface–Associated Calreticulin. Cancer Research, 2015, 75, 1603-1614.	0.4	86
56	Melanoma targeting with the loco-regional chemotherapeutic, Melphalan: From cell death to immunotherapeutic efficacy. Oncolmmunology, 2015, 4, e1054600.	2.1	4
57	GRP78-targeting Sensitizes Cancer Cells to Cytotoxic Effects of Photodynamic Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 149-161.	0.1	0
58	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. Blood, 2015, 126, 4917-4917.	0.6	0
59	Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses. Oncolmmunology, 2014, 3, e28837.	2.1	10
60	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs, 2014, 6, 1300-1313.	2.6	16
61	Statins impair glucose uptake in human cells. BMJ Open Diabetes Research and Care, 2014, 2, e000017.	1.2	37
62	Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. Translational Oncology, 2014, 7, 570-579.	1.7	17
63	Adenanthin targets proteins involved in the regulation of disulphide bonds. Biochemical Pharmacology, 2014, 89, 210-216.	2.0	36
64	Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis. Angiogenesis, 2014, 17, 347-357.	3.7	29
65	Iron Chelators in Photodynamic Therapy Revisited: Synergistic Effect by Novel Highly Active Thiosemicarbazones. ACS Medicinal Chemistry Letters, 2014, 5, 336-339.	1.3	30
66	B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia, 2014, 28, 1163-1167.	3.3	54
67	5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. European Journal of Cancer, 2014, 50, 1370-1381.	1.3	56
68	Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death and Differentiation, 2014, 21, 26-38.	5.0	187
69	Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells. Blood, 2014, 124, 1693-1693.	0.6	1
70	Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships. PLoS ONE, 2014, 9, e110291.	1.1	61
71	HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies. Blood, 2014, 124, 3641-3641.	0.6	0
72	SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell. Blood, 2014, 124, 3503-3503.	0.6	0

#	Article	IF	CITATIONS
73	GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death and Disease, 2013, 4, e741-e741.	2.7	52
74	Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter. Blood, 2013, 122, 1838-1838.	0.6	1
75	HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies. Blood, 2013, 122, 4406-4406.	0.6	1
76	Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies. Blood, 2013, 122, 4217-4217.	0.6	0
77	SK053 An Inhibitor Of Enzymes Involved In Allosteric Disulfide Bonds Formation Induces Differentiation Of Human AML Cells. Blood, 2013, 122, 4215-4215.	0.6	0
78	Contribution of ER Stress to Immunogenic Cancer Cell Death. , 2012, , 413-428.		2
79	Application of a proteomic approach to identify proteins associated with primary graft non-function after liver transplantation. International Journal of Molecular Medicine, 2012, 30, 755-764.	1.8	8
80	A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO Journal, 2012, 31, 1062-1079.	3.5	641
81	Statins Impair Glucose Uptake in Tumor Cells. Neoplasia, 2012, 14, 311-323.	2.3	37
82	Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity. Journal of Biological Chemistry, 2012, 287, 31983-31993.	1.6	19
83	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
84	Studies toward Novel Peptidomimetic Inhibitors of Thioredoxin–Thioredoxin Reductase System. Journal of Medicinal Chemistry, 2012, 55, 55-67.	2.9	44
85	Drug delivery technologies and immunological aspects of photodynamic therapy. Photochemical and Photobiological Sciences, 2011, 10, 647-648.	1.6	11
86	Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine and Growth Factor Reviews, 2011, 22, 99-108.	3.2	102
87	Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer. Molecules, 2011, 16, 4140-4164.	1.7	198
88	Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Frontiers in Bioscience - Landmark, 2011, 16, 277.	3.0	40
89	Antitumor effects of the combination of cholesterol reducing drugs. Oncology Reports, 2011, 26, 169-76.	1.2	7
90	Photodynamic therapy of cancer: An update. Ca-A Cancer Journal for Clinicians, 2011, 61, 250-281.	157.7	3,902

#	Article	IF	CITATIONS
91	PDT-induced inflammatory and host responses. Photochemical and Photobiological Sciences, 2011, 10, 653-663.	1.6	76
92	Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,. Blood, 2011, 118, 3723-3723.	0.6	0
93	Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,. Blood, 2011, 118, 3722-3722.	0.6	0
94	Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels. Blood, 2011, 118, 1661-1661.	0.6	0
95	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. Blood, 2010, 115, 3745-3755.	0.6	40
96	Genetic Modification of T Cells Improves the Effectiveness of Adoptive Tumor Immunotherapy. Archivum Immunologiae Et Therapiae Experimentalis, 2010, 58, 347-354.	1.0	2
97	Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1050-1071.	2.2	253
98	Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 53-71.	3.3	292
99	Statins can modulate effectiveness of antitumor therapeutic modalities. Medicinal Research Reviews, 2010, 30, 102-135.	5.0	37
100	Proteolytic pathways involved in modulation of CD20 levels. Autophagy, 2010, 6, 810-812.	4.3	4
101	Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach. Journal of Medicinal Chemistry, 2010, 53, 1509-1518.	2.9	38
102	Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. American Journal of Pathology, 2010, 176, 2658-2668.	1.9	115
103	Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Letters, 2010, 288, 57-67.	3.2	34
104	Photodynamic therapy-driven induction of suicide cytosine deaminase gene. Cancer Letters, 2010, 290, 216-222.	3.2	7
105	Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. Cancer Research, 2009, 69, 4235-4243.	0.4	96
106	Improvement of anti-tumor activity of photodynamic therapy through inhibition of cytoprotective mechanism in tumor cells. , 2009, , .		1
107	The possible role of factor H in colon cancer resistance to complement attack. International Journal of Cancer, 2008, 122, 2030-2037.	2.3	44
108	Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer, 2008, 8, 197.	1.1	59

#	Article	IF	CITATIONS
109	Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. PLoS Medicine, 2008, 5, e64.	3.9	115
110	Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells. International Journal of Oncology, 2007, 31, 1547-52.	1.4	3
111	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. International Journal of Oncology, 2007, , .	1.4	6
112	Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 731-741.	2.2	119
113	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. International Journal of Oncology, 2007, 30, 1413-25.	1.4	8
114	Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene, 2006, 25, 3365-3374.	2.6	163
115	Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway. Oncology Reports, 2006, 16, 1273.	1.2	7
116	Combined Effect of Proteasome and Calpain Inhibition on Cisplatin-Resistant Human Melanoma Cells. Cancer Research, 2006, 66, 7598-7605.	0.4	43
117	Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells inin vitro andin vivo studies. International Journal of Cancer, 2005, 117, 59-67.	2.3	40
118	Topical ALA–PDT modifies neutrophils' chemiluminescence, lymphocytes' interleukin-1beta secretion and serum level of transforming growth factor beta1 in patients with nonmelanoma skin malignancies. Photodiagnosis and Photodynamic Therapy, 2005, 2, 65-72.	1.3	13
119	The influence of photodynamic therapy on the immune response. Photodiagnosis and Photodynamic Therapy, 2005, 2, 283-298.	1.3	83
120	Prospects for p53-based cancer therapy Acta Biochimica Polonica, 2005, 52, 321-328.	0.3	21
121	Direct tumor damage mechanisms of photodynamic therapy Acta Biochimica Polonica, 2005, 52, 339-352.	0.3	222
122	Direct tumor damage mechanisms of photodynamic therapy. Acta Biochimica Polonica, 2005, 52, 339-52.	0.3	63
123	CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice. Clinical Cancer Research, 2004, 10, 4165-4175.	3.2	35
124	Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. International Journal of Oncology, 2004, 24, 1149.	1.4	17
125	AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. Leukemia Research, 2004, 28, 53-61.	0.4	4
126	Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 193-204.	2.2	5

#	Article	IF	CITATIONS
127	Role of the ubiquitin–proteasome pathway in the diagnosis of human diseases. Clinica Chimica Acta, 2004, 340, 27-40.	0.5	33
128	Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells. Clinical Cancer Research, 2004, 10, 4498-4508.	3.2	142
129	Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs. Oncology Reports, 2004, 11, 1121.	1.2	2
130	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncology Reports, 2004, 12, 1371-5.	1.2	11
131	Proteasome inhibitors in the treatment of cancer. Drug Discovery Today, 2003, 8, 575.	3.2	0
132	Natural mechanisms protecting against cancer. Immunology Letters, 2003, 90, 103-122.	1.1	181
133	Antitumor Effects of Photodynamic Therapy Are Potentiated by 2-Methoxyestradiol. Journal of Biological Chemistry, 2003, 278, 407-414.	1.6	113
134	Potential antitumor effects of statins (Review). International Journal of Oncology, 2003, 23, 1055.	1.4	56
135	Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver. Oncology Reports, 2003, 10, 1805.	1.2	2
136	Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clinical Cancer Research, 2003, 9, 3124-33.	3.2	31
137	Potential antitumor effects of statins (Review). International Journal of Oncology, 2003, 23, 1055-69.	1.4	74
138	Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clinical Cancer Research, 2003, 9, 5417-22.	3.2	46
139	A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. Oncology Reports, 2002, 9, 991.	1.2	3
140	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncology Reports, 2002, 9, 199.	1.2	0
141	Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology, 2002, 123, 1747.	0.6	10
142	Determination of Aldehyde Dehydrogenase (ALDH) Isozymes in Human Cancer Samples - Comparison of Kinetic and Immunochemical Assays. Molecules, 2002, 7, 896-901.	1.7	0
143	Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. International Journal of Cancer, 2002, 97, 746-750.	2.3	16
144	Stimulation of TNF-α production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. Cancer Chemotherapy and Pharmacology, 2002, 50, 213-222.	1.1	4

#	Article	IF	CITATIONS
145	Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. Journal of Cancer Research and Clinical Oncology, 2002, 128, 433-442.	1.2	6
146	Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. Clinical Cancer Research, 2002, 8, 1265-70.	3.2	26
147	Immunomodulation by anticancer chemotherapy: More is not always better (Review). International Journal of Oncology, 2001, 18, 417-24.	1.4	16
148	Direct stimulation of macrophages by IL-12 and IL-18 — a bridge too far?. Immunology Letters, 2000, 72, 153-157.	1.1	31
149	Antitumor effects of the combination therapy with TNF-α gene–modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Therapy, 2000, 7, 1581-1590.	2.2	25
150	INTERLEUKIN 18—INTERFERON γ INDUCING FACTOR—A NOVEL PLAYER IN TUMOUR IMMUNOTHERAPY?. Cytokine, 2000, 12, 332-338.	1.4	58
151	A Combination of Retinoic Acid and Proteasome Inhibitors for the Treatment of Leukemias Is Potentially Dangerous. Blood, 1999, 94, 1827-1828.	0.6	6
152	The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. Cancer Letters, 1999, 147, 67-75.	3.2	9
153	Effective chemo-immunotherapy of L1210 leukemiain vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. International Journal of Cancer, 1998, 77, 720-727.	2.3	39
154	Erythropoietin Prevents the Development of Interleukin-12–Induced Anemia and Thrombocytopenia But Does Not Decrease Its Antitumor Activity in Mice. Blood, 1998, 91, 4387-4388.	0.6	14
155	Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 455-462.	2.2	21
156	Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice. Cancer Immunology, Immunotherapy, 1997, 45, 100-108.	2.0	63
157	Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor \hat{I}_{\pm} in mice: Correlation betweenin vitro andin vivo results. , 1996, 66, 374-379.		27
158	Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunology, Immunotherapy, 1995, 40, 315-321.	2.0	35
159	Antitumor effects of the combination therapy with TNF-α gene–modified tumor cells and interleukin 12 in a melanoma model in mice. , 0, .		1
160	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncology Reports, 0, , .	1.2	1
161	IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. Oncology Reports, 0, , .	1.2	1
162	Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. Oncology Reports, 0, , .	1.2	3

#	Article	IF	CITATIONS
163	Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. Oncology Reports, 0, , .	1.2	Ο
164	Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. Oncology Reports, 0, , .	1.2	4